Nuvectra?

Quote
Those two were the only ones manufactured in the way that caused them to slip. The company has put quality controls in place to mitigate this process from happening again. Management stressed that there are no leads in any current patients that could potentially have this problem.

Yeah the revenue is low but that is mainly due to getting through the red tape that is hospital purchasing departments and setting up accounts with the new company. Also, Nuvectra isn't pretending to oust Nevro's HF-10, nor are they pretending to steal giant market share. But they will grab their fair share since they do have slightly better value propositions than Boston Sci and Medtronic.

Further, they are using their platform to get into SNS, which is a $500 mil market (and growing) monopolized by one single inferior product. Nuvectra's platform will smash that market in 2018-2019.
 






You really didn't just say that did you? Nuvectra will smash MDT and Nevro with its $13MM dollar 2017. That's the equivalent of 4 average MDT sales territories. Too ridiculous to comment any further
 






You misunderstood that post,

Go back and reread what I posted. I said they will smash the SNS (Sacral Nerve Stimulation) market, not SCS (Spinal Cord Stimulation) market. Neither Nevro nor MDT are in the SNS market. The only company selling SNS devices is Boston Scientific and Nuvectra's SNS platform performs better and the interface is easier for surgeons and patients to use than Boston Scientific's device. I think we will see significant market share stolen from Boston Sci in the SNS market around 2018-2019.

I never claimed Nuvectra would be a hero in the SCS market. Although they do have a slightly better SCS device than everyone except Nevro in the SCS market, there are brand loyalty headwinds to break. In the SCS market Nuvectra's Algovita works well, with quite a few success stories already, so there is no reason they can't conservatively grab 10-15% market share in a couple of years.

In fact, I've read quite a few quite a few successful trial stories for Algovita on the internet but haven't been able to locate any failed trial stories, which I'm sure there are at least some failed trials. If anyone can find a failed trial story please post a link.

Finally, the size of a company isn't an argument for a superior product. Just because MDT and BSI have huge sales forces and sales doesn't mean their product is better. As we see with the HF-10, the little guy with a better system can shake the entire market up.
 






Do your due diligence. MDT is only SNS company currently which is called Interstim. It's sad you think Boston has only SNS system when MDT has been the only SNS company for a long time.
 






anonymous said:
You misunderstood that post,

Go back and reread what I posted. I said they will smash the SNS (Sacral Nerve Stimulation) market, not SCS (Spinal Cord Stimulation) market. Neither Nevro nor MDT are in the SNS market. The only company selling SNS devices is Boston Scientific and Nuvectra's SNS platform performs better and the interface is easier for surgeons and patients to use than Boston Scientific's device. I think we will see significant market share stolen from Boston Sci in the SNS market around 2018-2019.

I never claimed Nuvectra would be a hero in the SCS market. Although they do have a slightly better SCS device than everyone except Nevro in the SCS market, there are brand loyalty headwinds to break. In the SCS market Nuvectra's Algovita works well, with quite a few success stories already, so there is no reason they can't conservatively grab 10-15% market share in a couple of years.

In fact, I've read quite a few quite a few successful trial stories for Algovita on the internet but haven't been able to locate any failed trial stories, which I'm sure there are at least some failed trials. If anyone can find a failed trial story please post a link.

Finally, the size of a company isn't an argument for a superior product. Just because MDT and BSI have huge sales forces and sales doesn't mean their product is better. As we see with the HF-10, the little guy with a better system can shake the entire market up.
Click to expand...

This post has a lot of incorrect information and conjecture backed up by nothing. Hopefully the original poster isn't making financial decisions or professional decisions based on incomplete/inaccurate information.

BSX's SCS system and NVTR's system are constant current. They're similar in that regards in comparison to constant voltage systems. Constant current has clinical advantages in that it "automatically" adjusts for changes to tissue impedance over time.

As someone else already mentioned above, MDT makes Interstim not BSX. The Interstim system needs work. The leads can fracture upon extraction unless you follow a specific technique. A technique was recently published (https://www.ncbi.nlm.nih.gov/pubmed/27705733). As it makes its way through the physician community, the fracture rate will hopefully decrease. That doesn't make the product design any better.

There's also another SNS system already on the market by Axonics. Though it's not available in the US yet. http://www.axonicsmodulation.com/

Axonics has Canadian approval already. They also MRI Conditional labeling for head and neck in Europe. Based on the timeline Drees described in the NVTR conference call, NVTR will beat Axonics to the US market but we'll see. Axonics already has approval in some geographies whereas NVTR has zero so far for its SNS system. Axonics's fixation method looks similar to MDTs. Both appear to use tined leads. I don't know how NVTRs lead is fixated. However, John Sowyer's name is on a bunch of patents for both MDT and NVTR (as Greatbatch). Maybe that one is tined too.

Would be interested in reading the Algovita success stories. Maybe you could post links to your success stories. There's no issues with TRIAL procedures posted on Maude through a simple search for "algovita" though a failed trial wouldn't get posted to maude unless it was a spectacular failure.
 






anonymous said:
You misunderstood that post,

Go back and reread what I posted. I said they will smash the SNS (Sacral Nerve Stimulation) market, not SCS (Spinal Cord Stimulation) market. Neither Nevro nor MDT are in the SNS market. The only company selling SNS devices is Boston Scientific and Nuvectra's SNS platform performs better and the interface is easier for surgeons and patients to use than Boston Scientific's device. I think we will see significant market share stolen from Boston Sci in the SNS market around 2018-2019.

I never claimed Nuvectra would be a hero in the SCS market. Although they do have a slightly better SCS device than everyone except Nevro in the SCS market, there are brand loyalty headwinds to break. In the SCS market Nuvectra's Algovita works well, with quite a few success stories already, so there is no reason they can't conservatively grab 10-15% market share in a couple of years.

In fact, I've read quite a few quite a few successful trial stories for Algovita on the internet but haven't been able to locate any failed trial stories, which I'm sure there are at least some failed trials. If anyone can find a failed trial story please post a link.

Finally, the size of a company isn't an argument for a superior product. Just because MDT and BSI have huge sales forces and sales doesn't mean their product is better. As we see with the HF-10, the little guy with a better system can shake the entire market up.
Click to expand...

Boston Scientific doesn't have a SNS system.
Medtronic does.
Go back to sales training. You missed some studf.
 






anonymous said:
I'm not sure about lies, but the recall you posted is a bit misleading.

The truth is that two patients did have issues with the leads overextending. The recall affected very few devices and was immediately fixed. There are no bad leads in any patients and there were controls implemented so that this specific manufacturing problem wouldn't happen again. All this was addressed in Nuvectra's Q3 Earnings call. In fact I believe NVTR management made the recall public and fixed the issue before the government even made it public.
Click to expand...

How do you know it was just two patients? It was 2 patient in Q3 according to the conference call. The recall letter talks about two risks - not just two patients.
 








































































2 questions please
1-how much time the Algeria SCS surgery take, compared to MDT BSX STJM +NVRO. I heard is substantially shorter.
2-Are their MRI friendly SCS's in the pipeline?
Thanks!
 












Top Bottom
Back
Quote